Sie befinden sich hier: Mitarbeiter > publist

Prof. Dr. med. Ulrich Mrowietz
Aktuelle Publikationen


2017

Keine Einträge

2016

Bierkarre H, Harder J, Cuthbert R, Emery P, Leuschner I Mrowietz U, Hedderich J, McGonagle D, Gläser R
Differential expression of antimicrobial peptides in psoriasis and psoriatic arthritis as a novel contributory mechanism for skin and joint disease heterogeneity
Scand J Rheumatol 2016;45(3):188-96
Online weight-loss coaching for patients with psoriasis: results of a pilot study.
Gerdes S, Dethlefs B, Personke Y, Storim J, Mrowietz U.
Br J Dermatol 2016;174(3):674-6
Steinz K, Mrowietz U
Psoriasis Management
HNO-Mitteilungen 2016;2:42-44
Mrowietz U, Gerdes S, Gläser R, Schröder O.
Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
Acta Derm Venereol. 2016;97(2):283-4
Gerdes S, Mrowietz U, Boehncke WH
Comorbidity in psoriasis
Hautarzt 2016;67(6):438-44

2015

Koch M, Baurecht H, Ried JS, Rodriguez E, Schlesinger S, Volks N, Gieger C, Rückert IM, Heinrich L, Willenborg C, Smith C, Peters A, Thorand B, Koenig W, Lamina C, Jansen H, Kronenberg F, Seissler J, Thiery J, Rathmann W, Schunkert H, Erdmann J, Barker J, Nair RP, Tsoi LC, Elder JT, Mrowietz U, Weichenthal M, Mucha S, Schreiber S, Franke A, Schmitt J, Lieb W, Weidinger S.
Psoriasis and Cardiometabolic Traits: Modest Association but Distinct Genetic Architectures.
J Invest Dermatol. 2015;135(5):1283-93
Baurecht H, Hotze M, Brand S, Büning C, Cormican P, Corvin A, Ellinghaus D, Ellinghaus E, Esparza-Gordillo J, Fölster-Holst R, Franke A, Gieger C, Hubner N, Illig T, Irvine AD, Kabesch M, Lee YA, Lieb W, Marenholz I, McLean WH, Morris DW, Mrowietz U, Nair R, Nöthen MM, Novak N, O'Regan GM; PAGE Consortium, Schreiber S, Smith C, Strauch K, Stuart PE, Trembath R, Tsoi LC, Weichenthal M, Barker J, Elder JT, Weidinger S, Cordell HJ, Brown SJ
Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms.
Am J Hum Genet. 2015;96(1):104-20
Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, Warren RB, Mrowietz U; TTOP study group
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study
J Eur Acad Dermatol Venereol 2015;29(6):1156-63
Mrowietz U, Chouela EN, Mallbris L, Stefanidis D, Marino V, Pedersen R, Boggs RL
Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study
J Eur Acad Dermatol Venereol 2015;29(6):1114-20
Yiu ZZ, Warren RB, Mrowietz U, Griffiths CE
Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes
J Dermatolog Treat 2015;26(4):329-34
Mrowietz U
Aldara-induced skin inflammation in mice: close enough to psoriasis?
Br J Dermatol 2015;172(2):313
Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C; SCULPTURE Study Group.
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
J Am Acad Dermatol 2015;73(1):27-36
Radtke MA, Mrowietz U, Feuerhahn J, Härter M, von Kiedrowski R, Nast A, Reich K, Strömer K, Wohlrab J, Augustin M
Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis
J Dtsch Dermatol Ges 2015;13(7):674-89
Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB
Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation
Dermatology 2015;231(2):184-90
Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemeny L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N
European s3-guidelines on the systemic treatment of psoriasis vulgaris - update 2015 - short version - edf in cooperation with eadv and ipc.
Journal of the European Academy of Dermatology and Venereology : JEADV 2015;29:2277-2294
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase iii, randomized controlled trial (esteem 2).
Br. J. Dermatol. 2015;173:1387-1399
Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, Augustin M
Drug safety of systemic treatments for psoriasis: Results from the german psoriasis registry psobest.
Arch. Dermatol. Res. 2015;307:875-883
Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Ostor AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J
A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases.
Adv. Ther. 2015;32:983-1028
Amber KT, Bloom R, Mrowietz U, Hertl M
TNF-?: a treatment target or cause of sarcoidosis?
Eur Acad Dermatol Venereol. 2015;29(11):2104-11
Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Br J Dermatol. 2015;173(4):949-61
Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT.
Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.
Am J Hum Genet. 2015;97(6):816-36

2014

Mrowietz U, de Jong EM, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, Warren RB
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
J Eur Acad Dermatol Venereol. 2014;28(4):438-53
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Br J Dermatol. 2014;170(2):435-44
Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, Reusch M, Strömer K, Wozel G, von Kiedrowski R, Rustenbach SJ, Purwins S, Reich K
German psoriasis registry PsoBest: objectives, methodology and baseline data.
J Dtsch Dermatol Ges. 2014;12(1):48-57
Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C; the CAIN457A2211 study group
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.
J Eur Acad Dermatol Venereol. 2014;28(12):1670-5
Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K
Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ).
Arch Dermatol Res. 2014;306(3):287-97
Hartig I, Schroeder JO, Mrowietz U
Neutrophilic Urticarial Dermatosis (NUD) in Probable Adult-Onset Still Disease Responding to Anakinra
J Clin Rheumatol. 2014;20(2):96-8
Steinz K, Gerdes S, Domm S, Mrowietz U.
Systemic treatment with fumaric Acid esters in six paediatric patients with psoriasis in a psoriasiscentre.
Dermatology 2014;229(3):199-204
Steinz K, Schubert S, Harder J, Gerdes S, Mrowietz U, Gläser R.
Bacterial soft tissue infection in psoriasis despite induction of epidermal antimicrobial peptides.
Exp. Dermatol. 2014;23(11):862-4
Mrowietz U, Steinz K, Gerdes S.
Psoriasis: to treat or to manage?
Exp Dermatol. 2014;23(10):705-9
Gerdes S, Laudes M, Neumann K, Baurecht H, Mrowietz U.
Wnt5a - a potential factor linking psoriasis to metabolic complications.
Exp Dermatol. 2014;23(6):438-40
Gerdes S, Osadtschy S, Buhles N, Baurecht H, Mrowietz U.
Cardiovascular biomarkers in patients with psoriasis.
Exp Dermatol. 2014;23(5):322-5
Mrowietz U
Fumarates for psoriasis: new insights into a small molecule prototype
Br J Dermatol 2014;171(4):687
Schreiber S, Luger T, Mittendorf T, Mrowietz U, Müller-Ladner U, Schröder J, Stallmach A, Bokemeyer B
Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology
Dtsch Med Wochenschr 2014;139(47):2399-404

2013

Mrowietz U, Domm S
Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?
J Eur Acad Dermatol Venereol 2013;27(8):1022-5
Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ
An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
Br J Dermatol. 2013;168(2):374-80
Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M
Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism.
Arch Dermatol Res. 2013;305(5):447-51
Nast A, Mrowietz U, Kragballe K, Puig L, Reich K, Warren RB, Schmitt J
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines.
Arch Dermatol Res. 2013;305(7):637-43
Nast A, Mrowietz U, Kragballe K, de Jong EM, Puig L, Reich K, Warren RB, Werner R, Kopkow C, Schmitt J
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study
Arch Dermatol Res. 2013;305(10):899-907
Mrowietz U
Cyclosporine as maintenance therapy in patients with severe psoriasis.
J Am Acad Dermatol. 2013;69(2):308-9
Mrowietz U, Reich K
Dear-Doctor-Letter Fumaderm® - What are the facts?
J Dtsch Dermatol Ges. 2013;11(10):1016-7
Mrowietz U, Reich K
Case reports of PML in patients treated for psoriasis.
N Engl J Med. 2013;369(11):1080-1
Förster A, Preussner LM, Seeger JM, Rabenhorst A, Kashkar H, Mrowietz U, Hartmann K
Dimethylfumarate induces apoptosis in human mast cells.
Exp Dermatol. 2013;22(11):719-24

2012

Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U.
Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?
Exp Dermatol. 2012;21(1):43-7
Reich K, Domm S, Mrowietz U.
Methotrexate therapy in dermatology.
J Dtsch Dermatol Ges. 2012;10(5):363-70.
Gerdes S, Mrowietz U
Comorbidities and psoriasis. Impact on clinical practice
Hautarzt 2012;63(3):202-213
Gerdes S, Osadtschy S, Buhles N, Mrowietz U
Zonulin may not be a marker of autoimmunity in patients with psoriasis
Acta Derm Venereol. 2012;92(2):171-2
Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U
Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases.
Br J Clin Pharmacol. 2012;74(3):424-36
Ellinghaus E, Stuart PE, Ellinghaus D, Nair RP, Debrus S, Raelson JV, Belouchi M, Tejasvi T, Li Y, Tsoi LC, Onken AT, Esko T, Metspalu A, Rahman P, Gladman DD, Bowcock AM, Helms C, Krueger GG, Koks S, Kingo K, Gieger C, Wichmann HE, Mrowietz U, Weidinger S, Schreiber S, Abecasis GR, Elder JT, Weichenthal M, Franke A.
Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL.
J Invest Dermatol 2012;132(4):1133-40
Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen MH, McManus R, Novelli G, Samuelsson L, Schalkwijk J, Ståhle M, Burden AD, Smith CH, Cork MJ, Estivill X, Bowcock AM, Krueger GG, Weger W, Worthington J, Tazi-Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winkelmann J, Wijmenga C, Langford C, Edkins S, Andrews R, Blackburn H, Strange A, Band G, Pearson RD, Vukcevic D, Spencer CC, Deloukas P, Mrowietz U, Schreiber S, Weidinger S, Koks S, Kingo K, Esko T, Metspalu A, Lim HW, Voorhees JJ, Weichenthal M, Wichmann HE, Chandran V, Rosen CF, Rahman P, Gladman DD, Griffiths CE, Reis A, Kere J; Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2, Nair RP, Franke A, Barker JN, Abecasis GR, Elder JT, Trembath RC.
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
Nat Genet. 2012;44(12):1341-8

2011

Gerdes S, Rostami-Yazdi M, Mrowietz U.
Adipokines and psoriasis.
Exp Dermatol. 2011;20(2):81-7
Gerdes S, Domm S, Mrowietz U.
Long-Term Treatment with Fumaric Acid Esters in an 11-Year-Old Male Child with Psoriasis.
Dermatology 2011;222(3):198-200
Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, Reich K, Mrowietz U.
Therapy of psoriasis in childhood and adolescence - a German expert consensus.
J Dtsch Dermatol Ges. 2011;Epub ahead of print
Wozel G, Klein E, Mrowietz U, Reich K, Sebastian M, Streit V.
Scalp psoriasis.
J Dtsch Dermatol Ges 2011;9(10):872
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N.
Definition of treatment goals for moderate to severe psoriasis: a European consensus.
Arch Dermatol Res 2011;303(1):1-10
Domm S, Mrowietz U.
Combination therapy in the treatment of psoriasis.
J Dtsch Dermatol Ges 2011;9(2):94-8
Mrowietz U, van de Kerkhof PC.
Management of palmoplantar pustulosis: do we need to change?
Br J Dermatol 2011;164(5):942-6
Mrowietz U, Kragballe K, Nast A, Reich K.
Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting.
J Eur Acad Dermatol Venereol 2011;25 Suppl 3:1-13
Mrowietz U, Macheleidt O, Eicke C.
Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®-gel): results.
J Dtsch Dermatol Ges 2011;9(10):815-31
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Müller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B.
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011].
J Dtzsch Dermatol Ges 2011;9 Suppl2:S1-104
Mrowietz U, Adamczyk A, Augustin M, Boehncke WH, Bonnekoh B, Gambichler T, Hengge U, Lippert U, Ludwig RJ, Luger T, Merk HF, Norgauer J, Philipp S, Reich K, Röcken M, Rostami-Yazdi M, Schön MP, Scola N, Sticherling M, Thaci D, Viehweg A, Wallbrecht K, Wozel G, Zouboulis CC, Neureither M.
Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse eines Experten-Workshops
J Dtsch Dermatol Ges 2011;Suppl 4:1-13
Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, Hsu MC, Yeilding N, Rader DJ, Mehta NN.
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.
J Am Acad Dermatol 2011;Epub ahead of print

2010

Harder J, Dressel S, Wittersheim M, Cordes J, Meyer-Hoffert U, Mrowietz U, Fölster-Holst R, Proksch E, Schröder JM, Schwarz T, Gläser R
Enhanced expression an secretion of antimicrobial peptides in atopic dermatitis an after superficial skin injury
J Invest Dermatol 2010;130(5):1355-64
Horn E, Domm S, Katz H, Lebwohl M, Mrowietz U, Kragballe K; for the International Psoriasis Council
Topical corticosteroids in psoriasis: strategies for improving safety.
J Eur Acad Dermatol Venereol. 2010;24(2):119-124.
Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation.
J Neuroinflammation. 2010;19;7(1):30
Rostami-Yazdi M, Clement B, Mrowietz U
Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients.
Arch Dermatol Res 2010 Jun 24. [Epub ahead of print];
Gerdes S, Franke J, Domm S, Mrowietz U.
Ustekinumab in the treatment of palmoplantar pustulosis.
Br J Dermatol. 2010;im Druck
Gerdes S, Mrowietz U
Psoriasis im Kindesalter. Optionen der systemischen Therapie.
Der Deutsche Dermatologe 2010;(9): 572-576
Domm S, Mrowietz U.
Combination therapy in the treatment of psoriasis.
J Dtsch Dermatol Ges. 2010;9(2):94-8
Gerdes S, Zahl VA, Weichenthal M, Mrowietz U.
Smoking and alcohol intake in severely affected patients with psoriasis in Germany.
Dermatology 2010;220(1):38-43
Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE, Li Y, Weidinger S, Eberlein B, Gieger C, Wichmann HE, Kunz M, Ike R, Krueger GG, Bowcock AM, Mrowietz U, Lim HW, Voorhees JJ, Abecasis GR, Weichenthal M, Franke A, Rahman P, Gladman DD, Elder JT.
Genome-wide association analysis identifies three psoriasis susceptibility loci.
Nat Genet. 2010;42(11):1000-4
Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL.
Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome.
J Allergy Clin Immunol 2010;125(2):500-2
Wozel G, Klein E, Mrowietz U, Reich K, Sebastian M, Streit V.
Scalp psoriasis.
J Dtsch Dermatol Ges. 2010;9(1):70-4
Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, Fournier H, Reinhard C, Ding J, Li Y, Tejasvi T, Gudjonsson J, Stoll SW, Voorhees JJ, Lambert S, Weidinger S, Eberlein B, Kunz M, Rahman P, Gladman DD, Gieger C, Wichmann HE, Karlsen TH, Mayr G, Albrecht M, Kabelitz D, Mrowietz U, Abecasis GR, Elder JT, Schreiber S, Weichenthal M, Franke A.
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.
Nat Genet 2010;42(11):991-995

2009

Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U.
Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action.
J Invest Dermatol. 2009;129(1):231-4
Lier GC, Mrowietz U, Wolfart M, Warnke PH, Wiltfang J, Springer IN.
Psoriasis of the tongue.
J Craniomaxillofac Surg 2009;37(1):51-3
Zhou Q, Mrowietz U, Rostami-Yazdi M.
Oxidative Stress in the Pathogenesis of Psoriasis
Free Radic Biol Med. 2009;47(7):891-905
Gerdes S, Kurrat W, Mrowietz U.
Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis.
Br J Dermatol. 2009;160(4): 736-40
Ulrich Mrowietz, Martin Rostami-Yazdi, Marcus Neureither, Kristian Reich
15 Jahre Fumaderm®: Fumarsäureester für die systemische Behandlung der mittelschweren und schweren Psoriasis vulgaris
J Dtsch Dermatol Ges. 2009;7 (Suppl 2),:3-16
Gerdes S, Zahl VA, Weichenthal M, Mrowietz U
Smoking and alcohol intake in severely affected patients with psoriasis in Germany
Dermatology 2009;Dec 9
Nast A, Augustin M, Boehncke WH, Klaus J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Sebastian M, Sterry W, Streit V, Weisenseel P, Rzany B.
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"
J Dtsch Dermatol Ges. 2009;Nov 12
Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkühn T, Radke M, Reich K, Rudwaleit M, Schreiber S
"TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept
Dtsch Med Wochenschr 2009;134(42):2132-6
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B
European S3-guidelines on the systemic treatment of psoriasis vulgaris
J Eur Acad Dermatol Venereol 2009;23(Suppl2):1-70
Yu H, Mrowietz U, Seifert O
Downregulation of SMAD2, 4 and 6 mRNA and TGFbeta receptor I mRNA in lesional and non-lesional psoriatic skin
Acta Derm Venereol 2009;89(4):1-70
Mrowietz U, Reich K
Psoriasis--new insights into pathogenesis and treatment
Dtsch Arztebl Int. 2009;106(1-2):11-18
Wigger-Albert W, Kuhlmann M, Wilhelm D, Mrowietz U, Eichhorn K, Ortega J, Bredehorst A, Wilhelm KP
Efficacy of a polyurethane dressing versus a soft silicone sheet on hypertrophic scars
J Wound Care 2009;18(5):208,210-214
Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T.
Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE)
J Dtsch Dermatol Ges. 2009;7(7):603-611
Harde V, Mrowietz U
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab
Harde V, Mrowietz U 2009;7(2):139-141
Mrowietz U, Seifert O
Keloid scarring: bench and bedside
Arch Dermatol Res. 2009;301(4):259-272
Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T
Cyclosporine therapy in dermatology
J Dtsch Dermatol Ges. 2009;7(5):474-479
Mrowietz U
Psoriasis Management - Was gibt es Neues?
Dt Dermatol 2009;10:1-3
Gerdes, S., Mrowietz, U.
Impact of Comorbidities on the Management of Psoriasis.
In: Yawalkar N (ed): Management of Psoriasis. Curr Probl Dermatol. Basel, Karger, 2009;38, pp 21-36
Mrowietz U, Domm S
Ekzem, Psoriasis, kutene Infektionen, Akne und andere häufige Hautkrankheiten
In: Dietel M, Suttrop N, Zeitz M: Harrisons Innere Medizin 2009;
Mrowietz U
Papulosquamous disorders
In: Burgdorf WHC, Plewig G, Wolff HH, Landthaler M: Braun-Falcos Dermatology, 3.Aufl. 2009;
Christophers E, Mrowietz U
Psoriasis
In: Burgdorf WHC, Plewig G, Wolhh HH, Landthaler M: Braun-Falcos Dermatology, 3. Aufl. 2009;

2008

Yazdi MR, Mrowietz U
Fumaric acid esters.
Clin Dermatol 2008;26(5):522-6
Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH
Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus.
Dermatology 2008;217(3):268-275
Austad J, Berth-Jones J, de la Brassinne M, Cambazard F, Kragballe K, Mrowietz U, Murphy G, Papp K, Segaert S, van de Kerkhof P, Wozel G
A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.
Br J Dermatol 2008;159(2):407-12
Adams S, Albrecht L, Augustin M, Barker J, Blauvelt A, Bourcier M, Parker R, Bush M, Carey W, Elewski B, Feldman S, Fowler J Jr, Fretzin S, Friedmann P, Fritsch P, Goddard A, Gordon K, Gratton D, Guenther L, Hamzavi I, Harvey D, Hata T, Ho V, Hsu S, Kaufmann R, Kerl H, Kimball R, Kircik L, Korman N, Krueger G, Kunynetz R, Langley R, Lasko C, Lee M, Leonardi C, Maari C, Magliocco M, Matheson R, Mrowietz U, Nayak A, Nigen S, Ogilvie A, Ortonne JP, Packman B, Papp K, Pehamberger H, Philipp S, Poulin Y, Prinz J, Reich K, Rich P, Rosoph L, Rustin M, Saurat JH, Schopf R, Sebastian M, Smith S, Sobell J, Sofen H, Stingl G, Strout C, Gauthier JS, Toth D, Trueb R, Uliasz A, Vender R, Wasel N, Wolfe J, Woodson J, Wozel G, Pruitt R.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet 2008;371(9625):1675-84
Eiling E, Schröder JO, Gross WL, Kreiselmaier I, Mrowietz U, Schwarz T
The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy--an autoinflammatory syndrome?
J Dtsch Dermatol Ges. 2008;6(8):626-31
Mrowietz U
Towards a new horizon
Arch Dermatol Res. 2008;300(1):1-2
Domm S, Cinatl J, Mrowietz U
The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
Br J Dermatol 2008;159(6):1217-28
Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U
Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis.
Br J Dermatol 2008;159(5):1116-23
Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators.Bagot M, Thio HB, Bissonnette R, Cambazard F, Martinez FC, Diaz Perez JL, Daudén E, de la Brassinne M, Fonseca E, Fritsch P, Galewicz D, Kaufmann R, Kerl H, Lambert J, Luger T, Marot L, Mrowietz U, Ogilve A, Poulin Y, Roecken M, Roszkiewicz J, Sánchez Carazo JL, van de Kerkhof P, Wasel N
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
Br J Dermatol 2008;158(3):558-66.
Domm S, Gläser R, Mrowietz U
Systemische Therapie in der Dermatologie. Ein praktischer Ratgeber zur Verordnung, Anwendung und Therapieüberwachung
Karger Verlag 2008;
Mrowietz U, Domm S
Harrisons Innere Medizin Band 1: Ekzem, Psoriasis, kutane Infektionen, Akne und andere häufige Hauterkrankungen.
ABW Wissenschaftsverlag 2008;Kapitel 53: S. 393-403

2007

Reischl J, Schwenke S, Beekman JM, Mrowietz U, Sturzebecher S, Heubach JF
Increased expression of Wnt5a in psoriatic plaques.
J Invest Dermatol 2007;127(1):163-9
Schmidt TJ, Ak M, Mrowietz U
Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters.
Bioorg Med Chem 2007;15(1):333-42
Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B.
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).
Arch Dermatol Res 2007;299(3): 111-138
Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B.
Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.
J Dtsch Dermatol Ges. 2007;5 Suppl 3:1-119
Reich K, Mrowietz U.
Treatment goals in psoriasis.
J Dtsch Dermatol Ges. 2007;5(7):566-74
Rott S, Küster RM, Mrowietz U.
Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko.
Br J Dermatol. 2007;157(1):191-2
Gerdes S, Shakery K, Mrowietz U.
Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells.
Br J Dermatol. 2007;156(5):838-42
van de Kerkhof PC, Mrowietz U, Segaert S, Kragballe K.
Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
Br J Dermatol. 2007;156(4):771-2
Rott S, Mrowietz U.
The use of infliximab in dermatology.
J Dtsch Dermatol Ges. 2007;5(8):655-60
Gerdes S, Mrowietz, U
Hilfe von außen bei Schuppenflechte. Topische Therapie der Psoriasis vulgaris.
CME 2007;4(6): 40-47
Mrowietz U, Rott S.
Survey regarding the status of senior physicians in German dermatology clinics
J Dtsch Dermatol Ges. 2007;5(11):1002-7
Mrowietz U.
In Process Citation
Hautarzt 2007;52(10):862-4
Mrowietz U, Altmeyer P, Bieber T, Röcken M, Schopf RE, Sterry W.
Treatment of psoriasis with fumaric acid esters (Fumaderm
J Dtsch Dermatol Ges. 2007;5(8):716-7.
Mrowietz U, Rott S
Evaluating Topical Treatments in Severe Psoriasis.
European Dermatology Review 2007;Issue I: 23-24

2006

Mrowietz U, Elder JT, Barker J.
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.
Arch Dermatol Res. 2006;298:309-319
Gerdes S, Mrowietz U.
Follicular rash during therapy with erlotinib (Tarceva).
J Dtsch Dermatol Ges 2006;4:855-857
Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schafer G; EUROPSO Patient Survey Group
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.
Br J Dermatol.  2006;155:729-736
Mrowietz U, Boehncke WH.
Leukocyte adhesion: a suitable target for anti-inflammatory drugs.
Curr Pharm Des. 2006;12:2825-2831
Gerdes S, Mrowietz U.
Classical topical therapy of psoriasis]
Hautarzt 2006;57:666-671
Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, Luger TA, Mrowietz U, Thestrup-Pedersen K.
Update on the use of ciclosporin in immune-mediated dermatoses.
Br J Dermatol.  2006;155:Suppl.2,1-16
Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G.
Therapy of psoriasis vulgaris with efalizumab
J Dtsch Dermatol Ges. 2006;4:511-512
Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G.
Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab
J Dtsch Dermatol Ges.  2006;4:444-447
Yu H, Bock O, Bayat A, Ferguson MW, Mrowietz U.
Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring.
J Plast Reconstr Aesthet Surg. 2006;59:221-229
Bock O, Schmid-Ott G, Malewski P, Mrowietz U
Quality of life of patients with keloid and hypertrophic scarring.
Arch Dermatol Res. 2006;297:433-438
Mrowietz U, Weichenthal M
Erythemato-squamöse Erkrankungen
In: A.Meves (Hg.) Intensivkurs Dermatologie. Urban und Fischer, München, Jena 2006;277-289
Rott, S., Mrowietz, U.
Anti-IL-2.
In: K.Asadullah, H.D.Volk, W.Sterry (Hg). Cytokine and Anti-cytokine Therapy in Dermatology. Transworld Research Network, Kerala, India. 2006;153-162

2005

Rott, S, Mrowietz, U
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies
BRITISH MEDICAL JOURNAL 2005;3307:16-720
Mrowietz U, Asadullah K
Dimethylfumarate for psoriasis: more than a dietary curiosity
TRENDS IN MOLECULAR MEDICINE 2005;11:43-48
Zhu, K., Mrowietz, U.
Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters
ARCHIVES OF DERMATOLOGICAL RESEARCH 2005;297:170-176
Bayat A, Walter JM, Bock O, Mrowietz U, Ollier WE, Ferguson MW.
Genetic susceptibility to keloid disease: mutation screening of the TGFbeta3 gene
BRITISH JOURNAL OF PLASTIC SURGERY 2005;58:914-921
Bock O, Yu H, Zitron S, Bayat A, Ferguson MW, Mrowietz U.
Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars
ACTA DERMATO-VENEREOLOGICA 2005;85:216-220
Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF; Multi-Centre Investigator Group.
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial
BRITISH JOURNAL OF DERMATOLOGY 2005;152:1219-1227
Reygagne P, Mrowietz U, Decroix J, de Waard-van der Spek FB, Acebes LO, Figueiredo A, Caputo R, Poncet M, Arsonnaud S.
Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis
Journal of Dermatological Treatment 2005;16 / 31-36
Mrowietz U, Barth J, Boehncke WH, Rosenbach T, Wozel G.
Behandlung der Psoriasis vulgaris und Psoriasis-Arthritis mit Etanercept
Journal der Deutschen Dermatologischen Gesellschaft 2005;3 / 470-472
Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U.
Psychosocial consequences of psoriasis--an empirical study of disease burden in 3753 affected people
HAUTARZT 2005;56 / 466-472
Yu H, Bock O, Bayat A, Ferguson MW, Mrowietz U
Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring.
BRITISH JOURNAL OF PLASTIC SURGERY 2005;59:106-111
Luger, TA., T. Bieber, M. Meurer, U. Mrowietz, T. Schwarz, J. Simon, T. Werfel, T. Zuberbier
Therapie des atopischen Ekzems mit Calcineurin-Inhibitoren
Journal der Deutschen Dermatologischen Gesellschaft 2005;3:386-392
Mrowietz, U., Zaumseil, R.-P.
Sequentielle Kombinationstherapie mit Psorcutan® Beta und Psorcutan® bei Patienten mit Psoriasis
Akt. Dermatol. 2005;7:458-463
Rott, S., Mrowietz, U.
Vom Nagellack zur systemischen Therapie.
Der Deutsche Dermatologe 2005;7:458-463
Mrowietz U
Erythematöse, erythematosquamöse und papulöse und papulonodöse Erkrankungen.
In: Braun-Falco et al., Dermatologie und Venerologie, Springer-Verlag, Heidelberg, 5. Aufl. 2005;
Mrowietz U
Der Hautarzt.
In: Reinhold-Keller, E., Gross, W.L. (Herausgeber): Vaskulitis. Steinkopff-Verlag, 2. Auflage, Darmstadt 2005;
Christophers, E, Mrowietz, U
Psoriasis
In: Braun-Falco et al., Dermatologie und Venerologie, Springer-Verlag, Heidelberg, 5. Auflage 2005;
Mrowietz U
Psoriasis.
In: Traupe H, Hamm H, Pädiatrische Dermatologie, Springer-Verlag, 2. Auflage, Heidelberg. 2005;
Christophers, E., Mrowietz, U.
Psoriasis.
In: Braun-Falco et al., Dermatologie und Venerologie, Springer-Verlag, Heidelberg, 5. Auflage. 2005;
Mrowietz U
Erythematöse, erythematosquamöse und papulöse und papulonodöse Erkrankungen.
In: Braun-Falco et al., Dermatologie und Venerologie, Springer-Verlag, Heidelberg, 5. Auflage. 2005;
Mrowietz U
Der Hautarzt.
In: Reinhold-Keller, E., Gross, W.L. (Herausgeber): Vaskulitis. Steinkopff-Verlag, 2. Auflage, Darmstadt. 2005;

2004

Soos N, Shakery K, Mrowietz U
Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis
AM J CLIN DERMATOL 2004;5:597-599
Lamprecht P, Moosig F, Adam-Klages S, Mrowietz U, Csernok E, Kirrstetter M, Ahmadi-Simab K, Schroder JO, Gross WL
Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor
ANNALS OF THE RHEUMATIC DISEASES 2004;63:1518-1520
Ormerod AD, Mrowietz U
Fumaric acid esters, their place in the treatment of psoriasis
BRITISH JOURNAL OF DERMATOLOGY 2004;150:630-632
Bayat A, Bock O, Mrowietz U, Ollier WE, Ferguson MW
Genetic susceptibility to keloid disease: transforming growth factor beta
EXPERIMENTAL DERMATOLOGY 2004;13:120-124

2003

Boehncke WH, Friedrich M, Mrowietz U
Stellenwert von Biologics in der Psoriasis-Therapie: Ein Konsensus-Papier der Arbeitsgruppe Psoriasis in der Arbeitsgemeinschaft Dermatologische Forschung
J Dtsch Dermatol Ges 2003;1:620-628
Haacke, TC, Mrowietz U
Therapie der Nagelpsoriasis
Aktuelle Dermatologie  2003;29:517-520
Mrowietz U
Psoriasistherapie - eine Herausforderung
Aktuelle Dermatologie  2003;29:499-500
Treumer F, Zhu K, Glaser R, Mrowietz U
Dimethylfumarate is a potent inducer of apoptosis in human T cells.
JOURNAL OF INVESTIGATIVE DERMATOLOGY  2003;121:1383-1388
Lahfa M, Mrowietz U, Koenig M, Simon JC
Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis.
EUROPEAN JOURNAL OF DERMATOLOGY  2003;13:261-265
Mrowietz U
Psoriasis therapy with biologicals
HAUTARZT 2003;54:224-229
Mrowietz U, Gläser R
Report of the 9th Psoriasis Specialty Congress, Bad Bentheim, 5 April 2003
HAUTARZT  2003;54-1131-1134
Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion.
ACTA DERMATO-VENEREOLOGICA  2003;83-351-353
Mrowietz U, Soós, N, Werner, P
Hämangiome - Neue Aspekte zur Klassifikation, Pathogenese und zu therapeutischen Strategien
Kinder- und Jugendmedizin  2003;3:100-105
Ghoreschi K, Mrowietz U, Rocken M
A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.
JOURNAL OF MOLECULAR MEDICINE-JMM  2003;81:471-480
Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA AND Röcken M
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
NATURE MEDICINE  2003;9:40-46
Bayat A, Bock O, Mrowietz U, Ollier WE and Ferguson MW
Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels.
PLASTIC AND RECONSTRUCTIVE SURGERY  2003;111:535-543
Christophers, E., Mrowietz, U.
Pustular eruptions of palms and soles.
In: Freedberg I.M., Eisen, A. Z., Wolff, K., Austen, K. F., Goldsmith, L. A., Katz, S. I. (Editors), Dermatology in general medicine, 6th edition 2003, Mc Graw-Hill, New York. 2003;
Mrowietz U
Clinical use and pharmacological profile of fuamric acid esters.
In: van de Kerkhof, P. (Editor), Textbook of Psoriasis, 2nd edition 2003, Blackwell, Oxford. 2003;
Christophers E, Mrowietz U
Psoriasis.
In: Freedberg I.M., Eisen, A. Z., Wolff, K., Austen, K. F., Goldsmith, L. A., Katz, S. I. (Editors), Dermatology in general medicine, 6th edition 2003, Mc Graw-Hill, New York. 2003;

2002

Bock, O., Mrowietz, U.
Keloide. Eine fibroproliferative Erkrankung unbekannter Ursache.
HAUTARZT 2002;53:515-523
Bock, O., Mrowietz, U., Gläser, R.
Schwärzliche Hyperpigmentierungen bei 3 Patienten.
HAUTARZT 2002;53:416-420
Dichmann, S., Mrowietz, U., Schöpf, E., Norgauer, J.
Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 2002;47:635-636
Mrowietz, U.
Treatment targeted to cell surface epitapes.
CLINICAL AND EXPERIMENTAL DERMATOLOGY 2002;27:591-596
Zhu, K., Gläser, R., Mrowietz, U.
Vitamin D3 and analogues modulate the expression of CSF-1 and its receptor in human dendritic cells.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 2002;297:1211-1217
Bayat, A., Bock, O., Mrowietz, U., Ollier, W.E., Ferguson, M.W.
Genetic susceptibility to keloid disease and transforming growth factor beta 2 polymorphismus.
BRITISH JOURNAL OF PLASTIC SURGERY  2002;55:283-286
Douglas, W.S., Poulin, Y., Decroix, J., Ortonne, J.P., Mrowietz, U., Gulliver, W., Krogstadt, A.L., Larsen, F.G., Iglesias, L., Buckley, C., Bibby, A.J.
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotrial in psoriasis vulgaris.
ACTA DERMATO-VENEREOLOGICA 2002;82:131-135

Zurück

Aktuelles:

 

Praktikum der Dermatologie

Das Hauptpraktikum Dermatologie beginnt am 17.10.2017 um 7:45 mit einer Einführungsvorlesung im Hörsaal der Hautklinik.  [mehr]

 


Dermatologie für Zahnmediziner

Die Veranstaltung beginnt am 24.10.2017  um 10:00 c.t. im Hörsaal der Hautklinik.


Lehrpreis 2017

Der Preis der Medizinischen Fakultät für die beste Lehre geht in diesem Jahr erneut an die Hautklinik  [mehr]


Neurodermitis Präventionsstudie

Studie zur frühkindlichen Anwendung von Hautpflegecremes [mehr]


Regulation von Botenstoffen der Entzündung

Kieler Team des Exzellenzclusters Entzündungsforschung deckt grundlegend neuen Mechanismus au. [mehr]


Prof. Fölster-Holst neue Präsidentin der ESPD

Professorin Dr. Regina Fölster-Holst, Klinik für Dermatologie, Venerologie und Allergologie, Medizinische Fakultät der Christian-Albrechts-Universität zu Kiel ist neue Präsidentin der Europäischen Gesellschaft für Kinderdermatologie (European Society for Pediatric Dermatology, ESPD). [mehr]


Patientenleitlinie zum Melanom erschienen

Der umfangreiche Ratgeber gibt in allgemeinverständlicher Sprache alle Empfehlungen zu Untersuchungen und Behandlungen wieder, die zuvor für die ärztliche Leitlinie zum Melanom erarbeitet worden sind.

Die Druckfassung zum kostenlosen Download [hier]   

 

Die Seite wurde zuletzt am 16.11.2017 um 11:51 geändert.